ATE384053T1 - Triazolderivate als tachykininrezeptor- antagonisten - Google Patents
Triazolderivate als tachykininrezeptor- antagonistenInfo
- Publication number
- ATE384053T1 ATE384053T1 AT03723929T AT03723929T ATE384053T1 AT E384053 T1 ATE384053 T1 AT E384053T1 AT 03723929 T AT03723929 T AT 03723929T AT 03723929 T AT03723929 T AT 03723929T AT E384053 T1 ATE384053 T1 AT E384053T1
- Authority
- AT
- Austria
- Prior art keywords
- tachykine
- receptor antagonists
- triazole derivatives
- triazole
- derivatives
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37612102P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384053T1 true ATE384053T1 (de) | 2008-02-15 |
Family
ID=29270766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723929T ATE384053T1 (de) | 2002-04-26 | 2003-04-22 | Triazolderivate als tachykininrezeptor- antagonisten |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7320994B2 (enExample) |
| EP (1) | EP1501809B1 (enExample) |
| JP (1) | JP4559087B2 (enExample) |
| KR (1) | KR100755577B1 (enExample) |
| CN (1) | CN1312136C (enExample) |
| AR (1) | AR039329A1 (enExample) |
| AT (1) | ATE384053T1 (enExample) |
| AU (1) | AU2003230829B8 (enExample) |
| BR (1) | BRPI0309534B8 (enExample) |
| CA (1) | CA2483159C (enExample) |
| CR (1) | CR7548A (enExample) |
| CY (1) | CY1107221T1 (enExample) |
| DE (1) | DE60318697T2 (enExample) |
| DK (1) | DK1501809T3 (enExample) |
| EA (1) | EA007720B1 (enExample) |
| EC (1) | ECSP045391A (enExample) |
| ES (1) | ES2298513T3 (enExample) |
| HR (1) | HRP20041008B1 (enExample) |
| IL (2) | IL164675A0 (enExample) |
| MX (1) | MXPA04010622A (enExample) |
| MY (1) | MY141559A (enExample) |
| NO (1) | NO333647B1 (enExample) |
| NZ (1) | NZ535886A (enExample) |
| PE (1) | PE20040600A1 (enExample) |
| PL (1) | PL212090B1 (enExample) |
| PT (1) | PT1501809E (enExample) |
| TW (1) | TWI265807B (enExample) |
| UA (1) | UA79113C2 (enExample) |
| WO (1) | WO2003091226A1 (enExample) |
| ZA (1) | ZA200408670B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US20060160794A1 (en) * | 2003-06-12 | 2006-07-20 | Amegadzie Albert K | Tachykinin receptor antagonists |
| PT1675846E (pt) * | 2003-10-24 | 2010-04-20 | Lilly Co Eli | Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
| CA2581454A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
| TW200716576A (en) * | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| DE602006018149D1 (de) * | 2005-07-25 | 2010-12-23 | Hoffmann La Roche | Substituierte triazolderivate und ihre verwendung als antagonisten des neurokinin-3-rezeptors |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| MX2009001710A (es) * | 2006-08-18 | 2009-02-25 | Syngenta Ltd | Uso de inhibidores hppd para el tratamiento de la depresion y/o sindrome de abstinencia asociados con drogas adictivas. |
| EP2065377B1 (en) | 2006-09-21 | 2011-11-23 | Eisai R&D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| EP2121610B1 (en) | 2006-12-20 | 2014-04-02 | Eli Lilly & Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| MX2010001135A (es) * | 2007-08-08 | 2010-03-09 | Neurosearch As | Nuevos derivados de 1,2,3-triazol, utiles como modulares de receptores de acetilcolina nicotinicos. |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| GB0823002D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isoxazoles derivatives with plant growth regulating properties |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| BR112017018620A2 (pt) | 2015-03-04 | 2018-04-17 | Vanda Pharmaceuticals Inc. | método de administração de tradipitanto, e, tradipitanto. |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| SG10201913616UA (en) | 2016-05-31 | 2020-03-30 | Kalvista Pharmaceuticals Ltd | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| CA3073998A1 (en) | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| CN119074729A (zh) * | 2017-11-17 | 2024-12-06 | 万达制药公司 | 使用川地匹坦治疗胃肠疾病的方法 |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| ES2980110T3 (es) | 2018-02-26 | 2024-09-30 | Ospedale San Raffaele Srl | Antagonistas de NK-1 para uso en el tratamiento del dolor ocular |
| JP7410137B2 (ja) * | 2018-06-08 | 2024-01-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントを用いる処置方法 |
| EP3856338B1 (en) * | 2018-09-28 | 2024-11-06 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021173641A1 (en) | 2020-02-25 | 2021-09-02 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| EP4125875A1 (en) | 2020-04-03 | 2023-02-08 | NeRRe Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| KR20230018485A (ko) | 2020-06-02 | 2023-02-07 | 네르 쎄라퓨틱스 리미티드 | 폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제 |
| CN111662235B (zh) * | 2020-06-23 | 2023-12-22 | 黄淮学院 | 一种苯甲酰基哒嗪衍生物及其制备方法 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2024138040A1 (en) | 2022-12-21 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| CN116082253B (zh) * | 2023-02-25 | 2025-04-25 | 浙大城市学院 | 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法 |
| WO2024223617A1 (en) * | 2023-04-24 | 2024-10-31 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| WO1995011880A1 (en) * | 1993-10-27 | 1995-05-04 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| AU2633897A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles |
| EP0915880B1 (en) | 1996-07-24 | 2007-10-10 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| EP1005454A4 (en) | 1997-08-06 | 2003-01-15 | Lilly Co Eli | 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS |
| EP1237874B1 (en) | 1999-12-17 | 2006-02-22 | Schering Corporation | Selective neurokinin antagonists |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
| JP2002123925A (ja) | 2000-10-13 | 2002-04-26 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
| DK1501808T3 (da) * | 2002-04-26 | 2008-10-13 | Lilly Co Eli | Tachykininreceptor-antagonister |
-
2003
- 2003-04-22 EA EA200401431A patent/EA007720B1/ru not_active IP Right Cessation
- 2003-04-22 AT AT03723929T patent/ATE384053T1/de active
- 2003-04-22 HR HRP20041008AA patent/HRP20041008B1/hr not_active IP Right Cessation
- 2003-04-22 US US10/512,249 patent/US7320994B2/en not_active Expired - Lifetime
- 2003-04-22 AU AU2003230829A patent/AU2003230829B8/en not_active Expired
- 2003-04-22 EP EP03723929A patent/EP1501809B1/en not_active Expired - Lifetime
- 2003-04-22 AR ARP030101377A patent/AR039329A1/es unknown
- 2003-04-22 BR BRPI0309534A patent/BRPI0309534B8/pt not_active IP Right Cessation
- 2003-04-22 DK DK03723929T patent/DK1501809T3/da active
- 2003-04-22 TW TW092109375A patent/TWI265807B/zh not_active IP Right Cessation
- 2003-04-22 MY MYPI20031515A patent/MY141559A/en unknown
- 2003-04-22 NZ NZ535886A patent/NZ535886A/en not_active IP Right Cessation
- 2003-04-22 ES ES03723929T patent/ES2298513T3/es not_active Expired - Lifetime
- 2003-04-22 CN CNB038091046A patent/CN1312136C/zh not_active Expired - Lifetime
- 2003-04-22 PE PE2003000400A patent/PE20040600A1/es not_active Application Discontinuation
- 2003-04-22 UA UA20041008646A patent/UA79113C2/uk unknown
- 2003-04-22 KR KR1020047017206A patent/KR100755577B1/ko not_active Expired - Lifetime
- 2003-04-22 MX MXPA04010622A patent/MXPA04010622A/es active IP Right Grant
- 2003-04-22 PT PT03723929T patent/PT1501809E/pt unknown
- 2003-04-22 JP JP2003587786A patent/JP4559087B2/ja not_active Expired - Lifetime
- 2003-04-22 DE DE60318697T patent/DE60318697T2/de not_active Expired - Lifetime
- 2003-04-22 WO PCT/US2003/010681 patent/WO2003091226A1/en not_active Ceased
- 2003-04-22 PL PL373504A patent/PL212090B1/pl unknown
- 2003-04-22 CA CA2483159A patent/CA2483159C/en not_active Expired - Lifetime
-
2004
- 2004-10-18 IL IL16467504A patent/IL164675A0/xx not_active IP Right Cessation
- 2004-10-25 CR CR7548A patent/CR7548A/es unknown
- 2004-10-26 ZA ZA200408670A patent/ZA200408670B/xx unknown
- 2004-10-26 EC EC2004005391A patent/ECSP045391A/es unknown
- 2004-11-24 NO NO20045120A patent/NO333647B1/no not_active IP Right Cessation
-
2008
- 2008-02-28 CY CY20081100235T patent/CY1107221T1/el unknown
-
2009
- 2009-04-07 IL IL198122A patent/IL198122A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| CY2017032I1 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
| ATE344798T1 (de) | Als histamin-h3-antagonisten geeignete indolderivate | |
| NO20051871D0 (no) | Opioid reseptorantagonister | |
| ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
| ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
| IS7625A (is) | Nýjar samrunnar imídazól afleiður | |
| ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| DE60023167D1 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
| PL373889A1 (en) | (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| ATE377008T1 (de) | Imidazolderivate als glutamatrezeptorantagonisten | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| ATE518834T1 (de) | 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten | |
| DE60214408D1 (de) | 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN | |
| ATE495168T1 (de) | Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten | |
| ATE504300T1 (de) | Harnstoffderivate als il-8-rezeptorantagonisten | |
| EE200300335A (et) | Histamiiniretseptori antagonistid | |
| ATE528291T1 (de) | Cyclopropylderivate als nk3 rezeptor-antagonisten | |
| DE60209885D1 (de) | Crf receptor antagonisten | |
| DE602004018527D1 (de) | Furanderivate als ep4-rezeptorantagonisten | |
| SI1501809T1 (sl) | Derivati triazola kot antagonisti tahikininskega receptorja |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1501809 Country of ref document: EP |